JP2013126995A5 - - Google Patents

Download PDF

Info

Publication number
JP2013126995A5
JP2013126995A5 JP2013027479A JP2013027479A JP2013126995A5 JP 2013126995 A5 JP2013126995 A5 JP 2013126995A5 JP 2013027479 A JP2013027479 A JP 2013027479A JP 2013027479 A JP2013027479 A JP 2013027479A JP 2013126995 A5 JP2013126995 A5 JP 2013126995A5
Authority
JP
Japan
Prior art keywords
seq
helix
amino acid
isolated polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013027479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013126995A (ja
JP5918155B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013126995A publication Critical patent/JP2013126995A/ja
Publication of JP2013126995A5 publication Critical patent/JP2013126995A5/ja
Application granted granted Critical
Publication of JP5918155B2 publication Critical patent/JP5918155B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2013027479A 2005-08-05 2013-02-15 組織保護ペプチド及びその使用 Expired - Fee Related JP5918155B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70574105P 2005-08-05 2005-08-05
US60/705,741 2005-08-05
US70627605P 2005-08-08 2005-08-08
US60/706,276 2005-08-08
US83173706P 2006-07-18 2006-07-18
US60/831,737 2006-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008525285A Division JP5274253B2 (ja) 2005-08-05 2006-08-07 組織保護ペプチド及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015020020A Division JP6158235B2 (ja) 2005-08-05 2015-02-04 組織保護ペプチド及びその使用

Publications (3)

Publication Number Publication Date
JP2013126995A JP2013126995A (ja) 2013-06-27
JP2013126995A5 true JP2013126995A5 (cg-RX-API-DMAC10.html) 2013-08-08
JP5918155B2 JP5918155B2 (ja) 2016-05-18

Family

ID=37728020

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008525285A Expired - Fee Related JP5274253B2 (ja) 2005-08-05 2006-08-07 組織保護ペプチド及びその使用
JP2013027479A Expired - Fee Related JP5918155B2 (ja) 2005-08-05 2013-02-15 組織保護ペプチド及びその使用
JP2015020020A Expired - Fee Related JP6158235B2 (ja) 2005-08-05 2015-02-04 組織保護ペプチド及びその使用
JP2016114010A Expired - Fee Related JP6491621B2 (ja) 2005-08-05 2016-06-08 組織保護ペプチド及びその使用
JP2018071318A Pending JP2018134084A (ja) 2005-08-05 2018-04-03 組織保護ペプチド及びその使用
JP2020013151A Pending JP2020078317A (ja) 2005-08-05 2020-01-30 組織保護ペプチド及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008525285A Expired - Fee Related JP5274253B2 (ja) 2005-08-05 2006-08-07 組織保護ペプチド及びその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015020020A Expired - Fee Related JP6158235B2 (ja) 2005-08-05 2015-02-04 組織保護ペプチド及びその使用
JP2016114010A Expired - Fee Related JP6491621B2 (ja) 2005-08-05 2016-06-08 組織保護ペプチド及びその使用
JP2018071318A Pending JP2018134084A (ja) 2005-08-05 2018-04-03 組織保護ペプチド及びその使用
JP2020013151A Pending JP2020078317A (ja) 2005-08-05 2020-01-30 組織保護ペプチド及びその使用

Country Status (25)

Country Link
US (7) US8071554B2 (cg-RX-API-DMAC10.html)
EP (5) EP1924276A4 (cg-RX-API-DMAC10.html)
JP (6) JP5274253B2 (cg-RX-API-DMAC10.html)
KR (7) KR20170027868A (cg-RX-API-DMAC10.html)
CN (2) CN101378772B (cg-RX-API-DMAC10.html)
AU (1) AU2006278264B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0614529A8 (cg-RX-API-DMAC10.html)
CA (3) CA2982909A1 (cg-RX-API-DMAC10.html)
DK (3) DK2540309T3 (cg-RX-API-DMAC10.html)
EA (1) EA015672B1 (cg-RX-API-DMAC10.html)
ES (3) ES2653864T3 (cg-RX-API-DMAC10.html)
HU (3) HUE026444T2 (cg-RX-API-DMAC10.html)
IL (3) IL189287A (cg-RX-API-DMAC10.html)
IN (1) IN2014CN02050A (cg-RX-API-DMAC10.html)
LT (2) LT2594279T (cg-RX-API-DMAC10.html)
MX (3) MX339613B (cg-RX-API-DMAC10.html)
NO (1) NO20081112L (cg-RX-API-DMAC10.html)
NZ (1) NZ565937A (cg-RX-API-DMAC10.html)
PL (3) PL2371855T3 (cg-RX-API-DMAC10.html)
PT (3) PT2594279T (cg-RX-API-DMAC10.html)
SG (2) SG2014007868A (cg-RX-API-DMAC10.html)
SI (3) SI2371855T1 (cg-RX-API-DMAC10.html)
UA (1) UA100222C2 (cg-RX-API-DMAC10.html)
WO (1) WO2007019545A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201101890B (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) * 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
EP1924276A4 (en) * 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
CN101460188B (zh) * 2006-06-07 2013-09-04 国立大学法人德岛大学 使用促红细胞生成素的局部缺血疾病的治疗
DK2081956T3 (da) * 2006-11-13 2013-06-24 Charite Universitaetsmedizin FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012051581A2 (en) * 2010-10-14 2012-04-19 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
US9566349B2 (en) * 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
CN102180948A (zh) * 2011-03-03 2011-09-14 复旦大学附属中山医院 一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) * 2011-05-05 2014-04-30 中国人民解放军第三军医大学 小分子多肽和小分子多肽脂质体及其运用
EP2736530B1 (en) * 2011-07-27 2018-06-06 Neumedicines, Inc Use of il-12 to generate endogenous erythropoietin
US20140249573A1 (en) * 2011-09-20 2014-09-04 A.A. Cash Technology Ltd. Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) * 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
CN105517561A (zh) * 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN104744593A (zh) * 2013-12-25 2015-07-01 深圳先进技术研究院 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) * 2014-05-13 2015-11-24 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105968172A (zh) * 2014-06-22 2016-09-28 马恒标 组织保护活性多肽sl2及其应用
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
ES2952448T3 (es) 2016-11-10 2023-10-31 Asc Regenity Ltd Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
WO2018157773A1 (zh) 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
US20210244791A1 (en) * 2018-04-08 2021-08-12 Brim Biotechnology, Inc. Application of pedf-derived short peptides in tendon healing
KR102300060B1 (ko) 2018-06-12 2021-09-08 주식회사 엘지에너지솔루션 2열 터미널 구조의 pcb 다이렉트 커넥터
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845B (zh) * 2022-12-27 2025-07-11 上海瑞吉康生物医药有限公司 相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6140120A (en) * 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
BR9609006A (pt) * 1995-06-07 1999-12-14 Ortho Pharma Corp Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
TR200103785T2 (tr) 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
WO2001083548A1 (en) * 2000-04-28 2001-11-08 Effector Cell Institute Novel derivative of cell chemotactic factor
AU3323002A (en) * 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP2004522445A (ja) * 2001-02-06 2004-07-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたエリスロポエチン（ｅｐｏ）
JP2005503127A (ja) * 2001-04-04 2005-02-03 ジェンオディセ エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
MXPA05000063A (es) 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
KR100478455B1 (ko) 2002-08-19 2005-03-22 삼성전자주식회사 전자렌지
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
ZA200505423B (en) 2002-09-09 2008-08-27 Warren Pharmaceuticals Inc Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2006512300A (ja) * 2002-10-03 2006-04-13 エピミューン インコーポレイテッド Ｈｌａ結合ペプチド及びその使用
JP2004305006A (ja) * 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
ATE482713T1 (de) * 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
ATE554186T1 (de) 2007-11-29 2012-05-15 Molecular Health Gmbh Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2297182A4 (en) * 2008-04-28 2012-08-15 Harvard College HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION
WO2011022056A2 (en) 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2009508471A5 (cg-RX-API-DMAC10.html)
SI2594279T1 (en) Tissue protective peptides and their uses
RU2648950C2 (ru) Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
JP2020040969A5 (cg-RX-API-DMAC10.html)
US20190016781A1 (en) Polynucleotides encoding immune modulating polypeptides
Kumar et al. IL-22: an evolutionary missing-link authenticating the role of the immune system in tissue regeneration
JP2022541657A5 (cg-RX-API-DMAC10.html)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP2016196480A5 (cg-RX-API-DMAC10.html)
US9688733B2 (en) Method for treating spinal cord injury using HMGB1 fragment
BR112021003410A2 (pt) anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos
CN105327350A (zh) 泛素化途径相关因子在调控辅助性t细胞功能中的应用
JP2017523225A (ja) インフルエンザウイルス感染に使用するためのインドール類
Wang et al. High level expression and purification of bioactive human α-defensin 5 mature peptide in Pichia pastoris
CN114573709B (zh) 携带趋化因子受体且靶向msln抗原的car t免疫细胞的制备及其用途
JP2016514672A (ja) 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン
JP2003189887A5 (cg-RX-API-DMAC10.html)
ES2390967T3 (es) Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
CN109369795B (zh) 一种调控巨噬细胞免疫功能活性的蛋白质及其应用
JP2009507474A5 (cg-RX-API-DMAC10.html)
CN109200271A (zh) 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用
JP2009542631A (ja) 自己免疫疾患、アレルギー性疾患及び炎症性疾患治療用薬剤組成物、並びにその伝達方法
Wang et al. Interferons as negative regulators of ILC2s in allergic lung inflammation and respiratory viral infections
CN106552259A (zh) 一种融合蛋白及其治疗疾病的用途
JP2021516668A5 (cg-RX-API-DMAC10.html)